Opioid Coprescription Through Risk Mitigation Guidance and Opioid Agonist Treatment Receipt

Original research
by
Run Min, Jeong, et al

Release Date

2024

Geography

Canada

Language of Resource

English

Full Text Available

Yes

Open Access / OK to Reproduce

Yes

Peer Reviewed

Yes

Objective

Is coprescription of hydromorphone tablets or sustained-release oral morphine (opioid risk mitigation guidance [RMG]) and opioid agonist treatment (OAT) associated with subsequent OAT receipt?

Findings/Key points

This study, which acknowledged the intermittent use of both medications, demonstrated that individuals who were coprescribed opioid RMG had higher adjusted probability of continued OAT receipt or reengagement compared with those not receiving opioid RMG.

Design/methods

This population-based, retrospective cohort study was conducted from March 27, 2020, to August 31, 2021, included individuals from 10 linked health administrative databases from British Columbia, Canada.

doi.org

Keywords

About PWUD
Clinical guidance
Evidence base
Safer supply
Substitution/OAT
Transitions in care/treatment